TASIGNA

Tasigna is one of the most popular cancer drugs in the world, with almost $2 billion in sales in 2016 alone. Prescribed to treat chronic myeloid leukemia, Tasigna has been found to cause a severe and rapid-onset atherosclerosis, a form of cardiovascular disease that a thickening of arterial walls. Atherosclerosis results in a reduced blood flow as the arterial walls narrow from a build-up of fibrofatty plaque and white blood cells. The lack of adequate blood circulation, primarily in the legs, can result in infections, tissue death, sometimes requiring amputation. Atherosclerosis caused by Tasgina may also lead to coronary artery disease, stroke and death... Tasigna is produced and sold by Novartis AG Pharmaceutical, a Swiss Big Pharma company with over $50 billion in annual sales. In 2015 the United States Department of Justice charged Novartis with $3.35 billion in overcharges and fines resulting from Novartis' use of illegal kickbacks to boost drug sales and submitting false claims..

Also known as: Tasigna Lawyer

Primary location: St. Louis United States